Pleural Mesothelioma

Pleural mesothelioma is the most common form of mesothelioma, accounting for approximately 80% of all diagnoses. It develops in the pleural membrane — the two-layered serous lining that encases the lungs and lines the chest cavity.¹

The pleura consists of two layers: the visceral pleura (covering the lung surface) and the parietal pleura (lining the chest wall, mediastinum, and diaphragm). Between these layers lies the pleural space, which contains a small volume of serous fluid that reduces friction during respiration. Malignant pleural mesothelioma most commonly begins in the parietal pleura and progressively encases the lung in a thick rind of tumor tissue.²

Like all forms of mesothelioma, pleural mesothelioma is caused primarily by asbestos exposure. When microscopic asbestos fibers are inhaled, they travel through the airways and penetrate into the lung parenchyma. From there, fibers migrate to the pleural surface via lymphatic drainage or direct penetration, where they become permanently embedded. Over a latency period of 20–50 years, these fibers cause chronic inflammation, oxidative stress, and DNA damage that lead to malignant transformation of mesothelial cells.³

The disease is staged using the TNM system (stages I–IV) and classified by cell type — epithelioid, sarcomatoid, or biphasic. Both staging and histology strongly influence treatment options and survival outcomes.¹

Pleural mesothelioma symptoms develop gradually and are frequently mistaken for more common respiratory conditions such as pneumonia, bronchitis, COPD, or even congestive heart failure. Symptoms may not appear until the tumor has grown extensively along the pleural surface, often decades after asbestos exposure.¹

Common symptoms include:

• Chest pain — Persistent, dull, aching pain in the chest wall or lower rib area, typically on one side. Pain worsens as the tumor grows into the chest wall, ribs, or intercostal nerves.²
• Pleural effusion — Fluid accumulation between the pleural layers is the presenting finding in up to 90% of pleural mesothelioma patients. It causes progressive shortness of breath and a sensation of chest pressure.⁴
• Dyspnea (shortness of breath) — Caused by pleural effusion, tumor growth restricting lung expansion, or both. Initially occurs with exertion and progresses to rest dyspnea.¹
• Chronic dry cough — A non-productive cough that persists despite standard treatment and worsens over time.
• Unexplained weight loss — Loss of more than 5–10% of body weight over a 6-month period is common and indicates advanced disease.²
• Fatigue — Profound, persistent tiredness that is not relieved by rest.
• Night sweats and low-grade fever — Present in some patients as a paraneoplastic phenomenon.

Advanced-stage symptoms:

• Dysphagia (difficulty swallowing) from esophageal compression
• Hoarseness from recurrent laryngeal nerve involvement
• Superior vena cava syndrome (facial swelling, upper extremity edema)
• Horner syndrome (ptosis, miosis, anhidrosis) from nerve invasion
• Palpable chest wall masses from tumor extension through the ribs

Any individual with a history of asbestos exposure who develops persistent chest pain, unexplained shortness of breath, or recurrent pleural effusion should be evaluated for mesothelioma. Early diagnosis improves eligibility for curative-intent treatments.⁴

Inhaled asbestos fibers are the primary cause of pleural mesothelioma. The mechanism of disease involves a multi-step process that unfolds over decades:³

• Inhalation — Asbestos fibers (typically 5–100 micrometers in length) are inhaled deep into the airways. Longer fibers (>5 μm) are most carcinogenic because they cannot be efficiently cleared by macrophages.³
• Fiber migration to the pleura — Fibers penetrate through the lung parenchyma to reach the visceral pleura, then transfer to the parietal pleura via pleural fluid circulation and lymphatic drainage. Fibers concentrate at lymphatic drainage points on the parietal pleura, known as "stomata" — which is why tumors often originate at these sites.³
• Chronic inflammation — Embedded fibers trigger a persistent inflammatory response. Macrophages attempt to engulf the fibers but fail (a process called "frustrated phagocytosis"), releasing reactive oxygen and nitrogen species that cause cumulative DNA damage.³
• Genetic damage — Ongoing oxidative stress and direct fiber-chromosome interactions lead to mutations and deletions in key tumor suppressor genes, particularly BAP1, NF2, and CDKN2A/p16.⁵
• Malignant transformation — After accumulating sufficient genetic damage over 20–50 years, mesothelial cells undergo uncontrolled proliferation, forming the characteristic rind-like tumor growth pattern along the pleural surface.²

Amphibole asbestos fibers (amosite, crocidolite) are considered more potent causes of pleural mesothelioma than chrysotile (serpentine) fibers, likely because their straight, needle-like shape allows deeper lung penetration and they resist chemical degradation more than curly chrysotile fibers. However, all forms of asbestos are confirmed human carcinogens.³

Common occupational settings where workers inhaled asbestos fibers include shipyards, power plants, oil refineries, construction sites, automotive brake and clutch repair shops, steel mills, textile mills, and asbestos mines and processing facilities. Military personnel, especially U.S. Navy sailors and shipyard workers, were among the most heavily exposed groups. Learn more about asbestos exposure sources.⁶

The primary risk factors for pleural mesothelioma are:¹

• Occupational asbestos exposure — The single most important risk factor. Workers in construction trades, shipbuilding, power generation, oil refining, steel production, and asbestos mining and manufacturing face the highest risk. Duration and intensity of exposure correlate with disease risk, though brief high-intensity exposures are sufficient to cause disease.³
• Secondary (take-home) exposure — Family members of asbestos workers who were exposed to fibers brought home on clothing, shoes, and hair. This primarily affected spouses who laundered contaminated work clothes.⁶
• Amphibole fiber type — Exposure to amphibole fibers (amosite, crocidolite, tremolite) carries a higher mesothelioma risk per fiber than chrysotile exposure, though all types are carcinogenic.³
• Male sex — Men account for approximately 80% of pleural mesothelioma cases, reflecting historical occupational exposure patterns. The sex ratio is narrowing as more secondary exposure cases in women are identified.¹
• Age over 65 — The median age at diagnosis is 72, reflecting the long latency period between exposure and disease onset.¹
• Germline BAP1 mutation — A hereditary mutation in the BAP1 tumor suppressor gene predisposes carriers to mesothelioma, uveal melanoma, and other cancers. BAP1 mutation carriers who are also exposed to asbestos have a particularly elevated risk.⁵

Notably, smoking is not a risk factor for pleural mesothelioma and does not increase the risk in asbestos-exposed individuals. This distinguishes mesothelioma from asbestos-related lung cancer, where the combined risk from smoking and asbestos exposure is multiplicative.¹

Diagnosing pleural mesothelioma requires a systematic approach combining clinical assessment, advanced imaging, and tissue biopsy with specialized pathological analysis.⁴

Clinical evaluation

The diagnostic process begins with a detailed history emphasizing occupational, military, and environmental asbestos exposure. Physical examination may reveal decreased breath sounds, dullness to percussion on one side (indicating pleural effusion), and digital clubbing in advanced cases.²

Imaging

• Chest X-ray — Initial imaging often reveals unilateral pleural effusion with or without pleural thickening. X-rays are insufficiently sensitive for diagnosis but raise suspicion for further workup.⁴
• Contrast-enhanced CT — The primary imaging modality. CT demonstrates circumferential or nodular pleural thickening, pleural effusion, mediastinal or chest wall invasion, and lymph node enlargement. CT is essential for clinical staging.⁴
• PET-CT — FDG-PET/CT assesses metabolic activity and is used for staging, detecting lymph node involvement, and identifying distant metastases. High SUV (standardized uptake value) correlates with more aggressive disease and poorer prognosis.⁴
• MRI — Superior to CT for evaluating diaphragmatic and chest wall invasion, MRI is particularly valuable for surgical planning in patients being considered for EPP or P/D.⁴

Tissue biopsy and pathology

A definitive diagnosis requires tissue biopsy, as pleural fluid cytology alone has a sensitivity of only 30–50% for mesothelioma.⁴

• VATS (video-assisted thoracoscopic surgery) — The gold-standard biopsy technique. VATS provides direct visualization of the pleural surfaces and allows collection of large tissue samples for histological analysis. Simultaneous talc pleurodesis can be performed to manage effusion.⁴
• CT-guided core needle biopsy — A less invasive alternative that provides tissue for diagnosis, though smaller samples may limit histological subtyping accuracy.⁴

Immunohistochemistry (IHC) is essential for confirming the diagnosis and distinguishing mesothelioma from metastatic adenocarcinoma or other pleural malignancies. A panel of positive markers (calretinin, WT1, cytokeratin 5/6, D2-40) and negative markers (CEA, TTF-1, MOC-31, BerEP4) establishes the diagnosis with high confidence. Loss of BAP1 nuclear staining and CDKN2A/p16 deletion (detected by FISH) are additional confirmatory markers.⁵

Pleural mesothelioma is the only type of mesothelioma with a formal TNM (Tumor, Node, Metastasis) staging system, established by the AJCC (8th edition, 2017) and refined by the IASLC Mesothelioma Staging Project. Accurate staging is essential for determining treatment eligibility and estimating prognosis.⁷

Stage I (Localized)

• Stage IA (T1, N0, M0) — Tumor involves the ipsilateral parietal pleura (chest wall, mediastinum, or diaphragm) with or without visceral pleural involvement. No lymph node involvement, no distant metastases.⁷
• Stage IB (T2-T3, N0, M0) — Tumor involves the visceral pleura with extension into the lung parenchyma or diaphragmatic muscle. No lymph node or distant spread.⁷

Median survival: 21+ months. Patients are typically eligible for curative-intent surgery (EPP or P/D) combined with chemotherapy and/or radiation.⁷

Stage II (Locally Advanced, Resectable)

• T1-T2, N1, M0 — Tumor as in stage I, with involvement of ipsilateral bronchopulmonary or hilar lymph nodes.⁷

Median survival: 14–19 months. Surgery may still be feasible, typically as part of a multimodal approach with neoadjuvant or adjuvant chemotherapy.⁷

Stage III (Locally Advanced, Borderline Resectable)

• Stage IIIA (T3, N1, M0) — Locally advanced tumor with ipsilateral lymph node involvement.
• Stage IIIB (T1-T3, N2, M0 or T4, any N, M0) — Tumor invading the chest wall, mediastinal structures, or contralateral pleura, and/or involvement of contralateral or supraclavicular lymph nodes.⁷

Median survival: 10–16 months. Treatment typically involves chemotherapy and/or immunotherapy, with surgery considered on a case-by-case basis at specialized centers.⁷

Stage IV (Metastatic)

• Any T, any N, M1 — Distant metastases to the contralateral lung, liver, bone, brain, peritoneum, or other sites.⁷

Median survival: 6–12 months. Treatment focuses on systemic therapy (chemotherapy, immunotherapy) and palliative care to manage symptoms and maintain quality of life.⁷

Treatment for pleural mesothelioma typically involves a multimodal approach — combining surgery, chemotherapy, immunotherapy, and/or radiation therapy. The optimal treatment plan depends on the stage of disease, cell type, patient performance status, and the expertise of the treating center.⁴

Surgery

Two major surgical procedures are used for pleural mesothelioma with curative intent:

• Extrapleural pneumonectomy (EPP) — Removes the affected lung, pleura, pericardium, and hemidiaphragm. EPP provides the most complete tumor removal but carries perioperative mortality of 3–7% and significant morbidity. It is generally reserved for younger patients with good cardiopulmonary reserve and epithelioid histology.⁴
• Pleurectomy/decortication (P/D) — Removes the pleural lining and all visible tumor while preserving the lung. Extended P/D (eP/D) includes resection of the diaphragm and/or pericardium. P/D has lower perioperative mortality (1–4%) and is increasingly favored over EPP, as studies show comparable overall survival with better quality of life and preserved lung function. See the EPP vs. P/D comparison.⁴

Chemotherapy

The standard first-line chemotherapy regimen is pemetrexed plus cisplatin, which improved median survival from 9.3 to 12.1 months in the pivotal phase III trial. Carboplatin is substituted for cisplatin in patients with renal impairment or who cannot tolerate cisplatin's side effects. Bevacizumab (Avastin) added to pemetrexed/cisplatin further improved survival to 18.8 months in the MAPS trial.⁴

Immunotherapy

Nivolumab plus ipilimumab (Opdivo + Yervoy) is FDA-approved as first-line treatment for unresectable pleural mesothelioma. The CheckMate 743 trial demonstrated median overall survival of 18.1 months versus 14.1 months with pemetrexed/platinum chemotherapy. The survival benefit was most pronounced in patients with non-epithelioid (sarcomatoid or biphasic) histology.⁸

Radiation therapy

• Adjuvant radiation — Delivered to the hemithorax after EPP to reduce local recurrence (hemithoracic intensity-modulated radiation therapy, or IMRT).
• Prophylactic tract irradiation — Radiation to biopsy and surgical port sites to prevent tumor seeding, though its routine use is debated.
• Palliative radiation — Targeted radiation for pain control in areas of chest wall invasion or symptomatic metastases.⁴

Palliative procedures

• Pleurodesis — Instillation of talc or other sclerosing agents into the pleural space to fuse the pleural layers and prevent recurrent effusion.⁴
• Indwelling pleural catheter (IPC) — A tunneled catheter that allows ambulatory drainage of pleural fluid at home, providing ongoing symptom relief.

The overall median survival for pleural mesothelioma is 12–21 months from diagnosis, with a 5-year survival rate of approximately 10%. However, prognosis varies considerably based on stage, cell type, treatment approach, and patient factors.¹

Survival by stage:

Survival by cell type:

Favorable prognostic factors include epithelioid histology, early-stage disease (I–II), younger age, good performance status (ECOG 0–1), female sex, absence of chest pain at diagnosis, normal platelet count, and normal LDH level.⁷

Patients treated at high-volume mesothelioma centers with multimodal therapy consistently achieve better outcomes than those treated at community centers with single-modality approaches.⁴

Prevention of pleural mesothelioma centers on eliminating asbestos exposure. Because there is no safe level of asbestos exposure, prevention strategies focus on strict occupational controls, environmental regulations, and public awareness:³

• Occupational safety — OSHA mandates a permissible exposure limit (PEL) of 0.1 fibers per cubic centimeter over an 8-hour time-weighted average, along with respiratory protection, decontamination procedures, and exposure monitoring for workers who may encounter asbestos.⁶
• Professional asbestos abatement — Any renovation or demolition of structures built before 1980 should include professional asbestos inspection and, if present, abatement by licensed contractors using proper containment and disposal methods.⁶
• Avoid disturbing asbestos materials — Intact asbestos-containing materials (insulation, floor tiles, pipe wrap, roof shingles) that are in good condition and undisturbed generally do not release fibers. They should be left in place and monitored, or professionally removed if they are deteriorating or will be disturbed by construction.
• Workplace decontamination — Workers should shower, change clothes, and leave work garments at the job site. Work clothing should never be brought home or laundered with household laundry to prevent secondary exposure to family members.⁶

For individuals with known asbestos exposure history, no validated screening protocol exists for early detection of pleural mesothelioma. Low-dose CT scanning, blood biomarkers (mesothelin, fibulin-3, HMGB1), and breath analysis are under active investigation but have not yet demonstrated sufficient sensitivity and specificity for population-based screening.⁴

Living with pleural mesothelioma requires a comprehensive approach to managing both the physical symptoms of the disease and the emotional impact on patients and families.

• Breathing management — Pleural effusion and tumor growth can severely restrict breathing. Procedures such as pleurodesis or indwelling pleural catheter placement can provide ongoing relief. Supplemental oxygen, breathing exercises, and energy conservation techniques help manage daily activities.
• Pain management — Chest wall pain is common and may require a multimodal approach including medications (NSAIDs, opioids, nerve blocks), radiation therapy to painful sites, and complementary therapies (acupuncture, massage).
• Nutritional support — Cancer cachexia (progressive weight loss and muscle wasting) affects many mesothelioma patients. An oncology-specialized dietitian can develop nutrition plans to maintain strength during treatment.
• Pulmonary rehabilitation — Structured exercise programs supervised by respiratory therapists help maintain lung function, physical stamina, and independence, particularly before and after surgery.
• Psychological support — A mesothelioma diagnosis can cause significant anxiety and depression. Support groups, counseling, and mental health resources help patients and caregivers cope with the emotional burden.
• Clinical trial access — Patients should discuss clinical trial eligibility with their oncologist. Trials provide access to emerging treatments including new immunotherapy combinations, targeted therapies, and tumor treating fields.
• Legal and financial planning — Patients may be eligible for compensation through asbestos trust funds, personal injury lawsuits, or VA benefits. Statutes of limitations apply, so early consultation with a mesothelioma attorney is important.

For additional information and support, visit the patients and families resource page.